Vesicular monoamine transporter 2: Role as a novel target for drug development
Vesicular monoamine transporter 2: Role as a novel target for drug development
复制标题
DOI：
10.1208/aapsj080478
复制
发表时间：
2006-01-01
期刊：
影响因子：
4.5
通讯作者：
Crooks, Peter A.
中科院分区：
文献类型：
--
作者：
Zheng, Guangrong;Dwoskin, Linda P.;Crooks, Peter A.
在中枢神经系统中，囊泡单胺转运蛋白 2 (VMAT2) 是唯一将细胞质多巴胺 (DA) 转移到突触囊泡中进行储存和随后胞吐释放的转运蛋白。通过药理学增强 VMAT2 对 DA 的螯合，从而防止细胞质中 DA 的氧化，可能是治疗帕金森病等疾病的一种策略。 VMAT2 也可能是开发精神兴奋剂滥用治疗的新靶点。本综述总结了VMAT2作为治疗靶点的可能作用、文献报道的VMAT2配体以及这些配体的构效关系，包括丁苯那嗪类似物、酮色林类似物、山贝林类似物和3-胺-2-苯基丙烯类似物。简要讨论了 VMAT2 的分子结构及其与配体结合的相关性。
In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. Pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA in the cytoplasm, may be a strategy for treating diseases such as Parkinson's disease. VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse. This review summarizes the possible role of VMAT2 as a therapeutic target, VMAT2 ligands reported in the literature, and the structure-activity relationship of these ligands, including tetrabenazine analogs, ketanserin analogs, lobeline analogs, and 3-amine-2-phenylpropene analogs. The molecular structure of VMAT2 and its relevance to ligand binding are briefly discussed.